Evidence map›Paper›PMID 40182085›Full record

ArticleSouthern African journal of HIV medicine2025

Pharmacokinetics, pharmacogenetics, and toxicity of co-administered efavirenz and isoniazid.

Jessica Taylor, Gary Maartens, Simiso Sokhela, Nomathemba Chandiwana, Godspower Akpomiemie, Francois Venter, Phumla Sinxadi

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Southern African journal of HIV medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03122262 (WRHI 060), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03122262 phase3completednot on this map

WRHI 060 (ADVANCE): A Randomised, Phase 3 Non-inferiority Study of DTG + TAF + FTC Compared With DTG + TDF + FTC and EFV + TDF + FTC in Patients Infected With HIV-1 Starting First-line Antiretroviral Therapy - Extension to 192 Weeks

TypeinterventionalSponsorProfessor Francois VenterRan2017 to 2022Enrolled1,110ConditionsHIV-1 InfectionArmsDolutegravir, Tenofovir Alafenamide, Truvada, Atripla
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jessica TaylorDivision of Clinical Pharmacology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.ORCID https://orcid.org/0000-0003-2705-1759
Gary MaartensDivision of Clinical Pharmacology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.ORCID https://orcid.org/0000-0003-3080-6606
Simiso SokhelaEzintsha, Wits Health Consortium, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.ORCID https://orcid.org/0000-0002-2707-1533
Nomathemba ChandiwanaEzintsha, Wits Health Consortium, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.ORCID https://orcid.org/0000-0001-7866-2651
Godspower AkpomiemieEzintsha, Wits Health Consortium, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.ORCID https://orcid.org/0000-0001-8982-1099
Francois VenterEzintsha, Wits Health Consortium, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.ORCID https://orcid.org/0000-0002-4157-732X
Phumla SinxadiDivision of Clinical Pharmacology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.ORCID https://orcid.org/0000-0002-1312-3523

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Objectives: We investigated the association between Method: We enrolled participants from the efavirenz arm of the ADVANCE trial (reference no.: NCT03122262), who received isoniazid and consented to genotyping. We compared efavirenz concentrations on and off isoniazid, stratified by Results: A total of 168 participants, median age 31 years, 57% female, had classifiable Conclusion:

Indexed as

CYP2B6efavirenzHIVisoniazidneurotoxicity

Identifiers

PMID40182085
PMCPMC11966721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.